Dextroamphetamine Saccharate

For the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults, the starting dose of mixed salts containing Dextroamphetamine Saccharate is typically 5 mg once or twice daily. Healthcare providers may increase the daily dosage in increments of 5 mg at weekly intervals until the optimal therapeutic response is achieved. The maximum recommended daily dose for adults is generally 40 mg, though some clinical situations may require higher doses under strict supervision. For Narcolepsy, the usual dose is 5 mg to 60 mg per day in divided doses, depending on the individual patient's response and tolerance.

Dextroamphetamine Saccharate is approved for use in children with ADHD. For children aged 3 to 5 years, the starting dose is usually 2.5 mg daily, increased by 2.5 mg weekly. For children aged 6 years and older, the starting dose is 5 mg once or twice daily, with weekly increases of 5 mg. It is important to note that this medication is not recommended for children under 3 years of age for ADHD. In pediatric narcolepsy (rare), the starting dose for children aged 6 to 12 is 5 mg daily, and for those 12 and older, 10 mg daily.

Renal Impairment

In patients with severe renal (kidney) impairment (GFR 15 to <30 mL/min/1.73 m²), the maximum dose should not exceed 20 mg per day. For those with end-stage renal disease (GFR <15 mL/min/1.73 m²), the medication is generally not recommended as the kidneys are the primary route of elimination, and drug accumulation could lead to toxicity.

Hepatic Impairment

While the liver metabolizes Dextroamphetamine Saccharate, specific dosage adjustment guidelines for hepatic (liver) impairment are not strictly defined in the standard labeling. However, healthcare providers usually exercise caution and may start at the lower end of the dosing range for patients with significant liver dysfunction.

Elderly Patients

Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

• Timing: Immediate-release versions are typically taken first thing in the morning, with subsequent doses 4 to 6 hours apart. Avoid taking doses late in the evening to prevent insomnia (difficulty sleeping).
• Food: The medication can be taken with or without food. However, consistency is key. Taking it the same way every day helps maintain stable blood levels.
• Administration: Extended-release capsules must be swallowed whole. Do not crush or chew them, as this destroys the controlled-release mechanism and increases the risk of side effects. If a patient has trouble swallowing, some capsules can be opened and the beads sprinkled on applesauce; this must be consumed immediately without chewing the beads.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F) in a tight, light-resistant container. Keep it in a secure location to prevent unauthorized use or theft.

If a dose is missed, it should be taken as soon as remembered. However, if it is late in the afternoon or evening, the missed dose should be skipped to avoid sleep disturbances. Do not "double up" or take two doses at once to make up for a missed one. Resume the regular schedule the following morning.

An overdose of Dextroamphetamine Saccharate is a medical emergency. Symptoms may include restlessness, tremor, rapid breathing, confusion, aggression, hallucinations, panic states, hyperpyrexia (extremely high fever), and rhabdomyolysis (muscle breakdown). Cardiovascular effects can include arrhythmias, hypertension (high blood pressure), or hypotension (low blood pressure) and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. If an overdose is suspected, contact your local poison control center or seek emergency medical care immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to severe fatigue and depression.

Common side effects are often dose-dependent and may diminish as the body adjusts to the medication. These include:

• Insomnia: Difficulty falling asleep or staying asleep. This is the most frequently reported side effect and often occurs if the medication is taken too late in the day.
• Decreased Appetite: Many patients experience a significant reduction in hunger, which can lead to weight loss. In children, this requires close monitoring of growth charts.
• Xerostomia (Dry Mouth): A sensation of dryness in the mouth due to reduced saliva flow. Patients are encouraged to stay hydrated or use sugar-free lozenges.
• Abdominal Pain: Mild stomach aches or nausea, particularly when the medication is taken on an empty stomach.
• Tachycardia: An increase in heart rate. Patients may feel their heart racing or fluttering.

• Emotional Lability: Irritability, mood swings, or feelings of nervousness and anxiety.
• Dizziness: A feeling of lightheadedness or spinning, which may increase the risk of falls.
• Diarrhea or Constipation: Changes in bowel habits are common as the CNS stimulant affects the enteric nervous system.
• Weight Loss: More pronounced than simple appetite suppression, sometimes requiring dietary intervention.
• Hyperhidrosis: Excessive sweating, even without physical exertion.

• Dyskinesia: Involuntary muscle movements or tics. If new tics develop, the medication may need to be discontinued.
• Visual Disturbances: Blurred vision or difficulty focusing the eyes.
• Libido Changes: Significant increases or decreases in sexual drive or function.
• Alopecia: Temporary thinning of the hair or hair loss.

> Warning: Stop taking Dextroamphetamine Saccharate and call your doctor immediately if you experience any of these serious symptoms.

• Cardiovascular Events: Chest pain, shortness of breath, or fainting. Stimulants can cause myocardial infarction (heart attack) or stroke, especially in those with pre-existing heart conditions.
• Psychiatric Symptoms: New or worsening psychosis (hallucinations, delusional thinking) or mania. Patients may see things that aren't there or become abnormally suspicious.
• Circulatory Problems: Numbness, pain, or skin color changes (from pale to blue to red) in the fingers or toes (Raynaud’s phenomenon).
• Priapism: Painful and prolonged erections (lasting more than 4 hours), which require urgent surgical intervention to prevent permanent tissue damage.
• Serotonin Syndrome: If taken with other serotonergic drugs, symptoms like agitation, hallucinations, rapid heart rate, fever, muscle twitching, or stiffness may occur.

Prolonged use of Dextroamphetamine Saccharate can lead to several chronic issues:

• Growth Suppression: In pediatric patients, long-term use has been associated with a temporary slowing in growth rate (both height and weight). Healthcare providers typically monitor growth and may suggest "medication holidays."
• Tolerance and Dependence: Over time, the body may require higher doses to achieve the same effect. Physical and psychological dependence can develop, making it difficult to stop the drug without experiencing withdrawal symptoms.
• Cardiovascular Strain: Chronic elevation of blood pressure and heart rate can lead to long-term cardiac remodeling or hypertension.

Dextroamphetamine Saccharate carries a prominent FDA Black Box Warning regarding its potential for abuse and dependence. According to the FDA, amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly. Furthermore, misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.

Report any unusual symptoms or side effects to your healthcare provider immediately to ensure safe and effective treatment.

Dextroamphetamine Saccharate is a powerful stimulant that requires careful medical supervision. It should only be used by the person for whom it was prescribed. Sharing this medication is illegal and dangerous. Before starting treatment, patients must undergo a thorough cardiovascular screening, including a blood pressure check and an electrocardiogram (ECG) if there is a family history of heart disease.

Abuse, Misuse, and Addiction: Dextroamphetamine Saccharate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Dextroamphetamine Saccharate, can result in overdose and death. Before prescribing, healthcare providers must assess each patient's risk for abuse and monitor them throughout treatment.

Risks of Sudden Death: Sudden death has been reported in association with CNS stimulant treatment at recommended doses in pediatric patients with structural cardiac abnormalities or other serious heart problems. In adults, sudden death, stroke, and myocardial infarction have been reported. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, or serious heart rhythm arrhythmias.

• Cardiovascular Risks: This medication can cause an increase in blood pressure (average increase of 2-4 mmHg) and heart rate (average increase of 3-6 bpm). It should be used with extreme caution in patients with hypertension or other underlying cardiac conditions.
• Psychiatric Risks: Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic conditions. There is a risk of induction of a mixed/manic episode in patients with bipolar disorder.
• Seizures: There is some clinical evidence that stimulants may lower the convulsive threshold in patients with a prior history of seizures. If seizures occur, the drug should be discontinued.
• Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant use.

Patients on Dextroamphetamine Saccharate require regular follow-up appointments. Healthcare providers will typically monitor:

• Blood Pressure and Heart Rate: At every visit to detect hypertension or tachycardia.
• Growth (Height and Weight): In children and adolescents to ensure they are meeting developmental milestones.
• Psychiatric Status: Monitoring for the emergence of anxiety, aggression, or depression.
• CBC and Liver Function: Periodic blood tests may be ordered to ensure no systemic toxicity is occurring, although this is less common than cardiac monitoring.

This medication may cause dizziness, tremors, or blurred vision. Until you know how Dextroamphetamine Saccharate affects you, use caution when driving a motor vehicle or operating heavy machinery. While it often improves focus, the potential for sudden "crashes" as the medication wears off can impair reaction times.

Alcohol should be strictly avoided while taking Dextroamphetamine Saccharate. Alcohol can alter the way the medication is released in the body (particularly with extended-release forms), leading to a rapid "dose dumping" that increases the risk of toxicity. Furthermore, the stimulant effects of the drug can mask the sedative effects of alcohol, leading to a higher risk of alcohol poisoning or dangerous behavior.

Do not stop taking this medication abruptly. Sudden cessation after prolonged use can result in a "crash," characterized by extreme fatigue, depression, sleep disturbances, and increased appetite. Healthcare providers will provide a tapering schedule to gradually reduce the dose and minimize withdrawal symptoms.

> Important: Discuss all your medical conditions, especially any history of heart problems or mental health issues, with your healthcare provider before starting Dextroamphetamine Saccharate.

• Monoamine Oxidase Inhibitors (MAOIs): Dextroamphetamine Saccharate must not be taken within 14 days of using an MAOI (such as selegiline, phenelzine, or tranylcypromine). This combination can trigger a hypertensive crisis—a sudden, life-threatening spike in blood pressure that can lead to stroke or organ failure.

• Serotonergic Drugs: Using this medication with SSRIs (e.g., fluoxetine), SNRIs (e.g., venlafaxine), or triptans increases the risk of Serotonin Syndrome. This is a potentially fatal condition caused by an excess of serotonin in the nervous system.
• CYP2D6 Inhibitors: Drugs that inhibit the CYP2D6 enzyme (like paroxetine or quinidine) can slow down the metabolism of dextroamphetamine, leading to dangerously high levels of the stimulant in the blood.
• Alkalinizing Agents: Substances that increase the pH of the stomach or urine (such as sodium bicarbonate or certain antacids) can increase the absorption and decrease the excretion of the drug, significantly boosting its effects and toxicity risk.

• Antihypertensives: Dextroamphetamine can antagonize (work against) the effects of blood pressure medications, making them less effective and requiring dosage adjustments of the antihypertensive agent.
• Tricyclic Antidepressants (TCAs): These may enhance the cardiovascular effects of amphetamines, leading to striking increases in blood pressure or heart rate.
• Acidifying Agents: Urinary acidifying agents (like ascorbic acid/Vitamin C or ammonium chloride) increase the excretion of dextroamphetamine, potentially reducing its therapeutic effectiveness.

• Fruit Juices and Vitamin C: Acidic juices (like orange or grapefruit juice) and high doses of Vitamin C can act as acidifying agents. If consumed near the time of dosing, they may reduce the amount of medication absorbed by the gut.
• Caffeine: Consuming large amounts of caffeine (coffee, tea, energy drinks) while on stimulants can lead to excessive jitteriness, palpitations, and increased blood pressure.
• High-Fat Meals: As noted in the PK profile, high-fat meals can delay the onset of action of the medication, which may be problematic for patients needing immediate symptom relief in the morning.

• St. John’s Wort: May increase the risk of serotonin syndrome when combined with amphetamines.
• Melatonin: While some use it to combat stimulant-induced insomnia, it can sometimes cause morning grogginess when combined with the tail-end of a stimulant's effects.
• Ginseng: May have additive stimulant effects, leading to increased heart rate and anxiety.

• Corticosteroids: Amphetamines may cause a significant elevation in plasma corticosteroid levels; this is greatest in the evening.
• Urinary Steroids: The medication may interfere with urinary steroid determinations.
• Drug Screenings: Dextroamphetamine will result in a positive test for "amphetamines" on standard urine drug screens. Patients should disclose their prescription to the testing laboratory.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter cold medicines containing decongestants (like pseudoephedrine) can interact dangerously with Dextroamphetamine Saccharate.

Dextroamphetamine Saccharate is strictly prohibited in the following circumstances:

• Advanced Arteriosclerosis: Hardening of the arteries can be exacerbated by the blood-pressure-raising effects of stimulants, leading to a high risk of vascular rupture or blockage.
• Symptomatic Cardiovascular Disease: Any active heart disease, including coronary artery disease or heart failure, poses a severe risk of sudden cardiac death when stimulants are introduced.
• Moderate to Severe Hypertension: Because the drug inherently raises blood pressure, it can push patients with existing hypertension into a hypertensive crisis.
• Hyperthyroidism: The overactive thyroid already puts strain on the heart; adding a CNS stimulant can lead to thyroid storm or severe cardiac arrhythmias.
• Glaucoma: Amphetamines can cause mydriasis (dilation of the pupils), which increases intraocular pressure and can lead to permanent vision loss in patients with narrow-angle glaucoma.
• Hypersensitivity: Any known allergy to amphetamines or any components of the formulation. Anaphylaxis, though rare, is a medical emergency.
• Agitated States: Patients who are in a state of extreme agitation or anxiety may see these symptoms worsen significantly.
• History of Drug Abuse: Due to the high potential for addiction, the drug is generally contraindicated in those with a history of substance use disorder.

Conditions requiring a careful risk-benefit analysis include:

• Tics and Tourette’s Syndrome: Stimulants may trigger or worsen motor and phonic tics. A careful family history should be taken before initiation.
• Bipolar Disorder: There is a high risk of inducing a manic episode. Stimulants should only be used if the bipolar disorder is well-controlled with mood stabilizers.
• Seizure Disorders: As the drug may lower the seizure threshold, it should be used with caution in patients with epilepsy.

Patients who have had an allergic reaction to other stimulant medications, such as Lisdexamfetamine (Vyvanse) or Methylphenidate (Ritalin), should be closely monitored, as cross-sensitivity can occur, although it is more common among different amphetamine salts themselves.

> Important: Your healthcare provider will evaluate your complete medical history, including family cardiac history, before prescribing Dextroamphetamine Saccharate.

Dextroamphetamine Saccharate is classified under FDA Pregnancy Category C. Data from human studies are limited, but animal studies have shown potential for embryotoxicity and increased risk of fetal loss. Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience withdrawal symptoms such as agitation and significant lassitude (lack of energy). It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Amphetamines, including Dextroamphetamine Saccharate, are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants (such as tachycardia, irritability, and poor weight gain), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Most healthcare providers recommend formula feeding if the mother must remain on stimulant therapy.

While highly effective for ADHD in children aged 3 and older, the long-term effects of stimulants on the developing brain are still being studied. The most significant concern is the suppression of growth. Clinical data suggests that children treated with stimulants may experience a temporary slowing in height and weight gain. Healthcare providers often implement "drug holidays" during summer breaks to allow for catch-up growth. It is not approved for use in children under 3 years of age.

Elderly patients (aged 65 and older) are at a higher risk for cardiovascular side effects. They are also more likely to have reduced renal clearance, which can lead to higher blood levels of the drug. Stimulants can also increase the risk of confusion or falls in the elderly. Polypharmacy (taking multiple medications) in this age group significantly increases the risk of dangerous drug interactions.

In patients with severe renal impairment, the kidneys cannot effectively filter the drug out of the system. This leads to a longer half-life and higher peak concentrations. For patients with a GFR between 15 and 30, the maximum dose is 20 mg. The drug is not recommended for patients with a GFR below 15 or those on dialysis, as the drug is not significantly removed by hemodialysis.

Since the liver (via CYP2D6) is responsible for a portion of the drug's metabolism, patients with severe hepatic impairment (Child-Pugh Class C) should be monitored closely. While specific dose reductions aren't mandated in the label, a slower titration schedule is often employed to prevent toxicity.

> Important: Special populations require individualized medical assessment and more frequent monitoring to ensure safety.

Dextroamphetamine Saccharate is a sympathomimetic amine that acts as a potent CNS stimulant. Its primary molecular target is the Trace Amine-Associated Receptor 1 (TAAR1), a G protein-coupled receptor found in the presynaptic terminal. Activation of TAAR1 increases cyclic AMP production, which triggers the phosphorylation of the Dopamine Transporter (DAT). This causes the transporter to reverse its direction, pumping dopamine out of the neuron. Simultaneously, the drug inhibits the Vesicular Monoamine Transporter 2 (VMAT2), preventing the storage of monoamines in vesicles and increasing their cytoplasmic concentration. This dual action results in a massive increase in synaptic dopamine and norepinephrine, particularly in the prefrontal cortex and striatum.

The pharmacodynamic effects include increased systolic and diastolic blood pressure and weak bronchodilator and respiratory stimulant action. At therapeutic doses, there is no evidence that it acts as a direct agonist on postsynaptic receptors. The duration of effect for immediate-release forms is roughly 4 to 6 hours, while the saccharate salt contributes to the extended profile in mixed salt formulations, extending the effect to 10-12 hours in XR versions. Tolerance to the anorectic (appetite-suppressing) effect usually develops within a few weeks.

| Parameter | Value |

|---|---|

| Bioavailability | >75% (Rapidly absorbed) |

| Protein Binding | ~20% |

| Half-life | 10-13 hours (Adults), 7-9 hours (Children) |

| Tmax | 3 hours (IR), 7-8 hours (XR) |

| Metabolism | Hepatic (CYP2D6 deamination) |

| Excretion | Renal (pH dependent; 30-40% unchanged) |

• Molecular Formula: (C9H13N)2 · C6H10O8
• Molecular Weight: 454.5 g/mol
• Solubility: Soluble in water; slightly soluble in alcohol.
• Structure: It is the saccharate salt of the dextrorotatory isomer of amphetamine. The saccharate moiety (derived from saccharic acid) provides a unique crystallization and dissolution profile compared to the sulfate or aspartate salts.

Dextroamphetamine Saccharate is a CNS Stimulant and a member of the Phenethylamine class. It is chemically related to other stimulants like methamphetamine and MDMA, but its specific structure and salt form are optimized for the treatment of ADHD and narcolepsy.